2019
DOI: 10.2478/acph-2020-0008
|View full text |Cite
|
Sign up to set email alerts
|

Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the “analytical quality by design” approach

Abstract: A UPLC-MS method for the estimation of atazanavir sulfate was developed using the "analytical quality by design" approach. The critical chromatographic quality attributes identified were retention time, theoretical plates and peak tailing. The critical method parameters established were percent of organic modifier, flow rate and injection volume. Optimization performed using Box-Behnken Design (BBD) established 10 % organic modifier, 0.4 mL min -1 flow rate and 6-µL injection volume as the optimum method condi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 28 publications
0
7
0
Order By: Relevance
“…In the case of an HPLC/UHPLC method, these CMAs can be peak symmetry, tailing factor, peak width, analysis time, the resolution between two peaks, theoretical plates, signal-to-noise ratio, etc. (40)(41)(42)(43). In the case of a complex matrix (e.g., plant extract, biological matrix) the definition of CMA can be difficult (if in any condition the CMA varies between the preferred intervals, it cannot be considered a CMA) (44).…”
Section: Quality-by-design In the Development Of Analytical Methods And Pharmaceutical Manufacturingmentioning
confidence: 99%
See 3 more Smart Citations
“…In the case of an HPLC/UHPLC method, these CMAs can be peak symmetry, tailing factor, peak width, analysis time, the resolution between two peaks, theoretical plates, signal-to-noise ratio, etc. (40)(41)(42)(43). In the case of a complex matrix (e.g., plant extract, biological matrix) the definition of CMA can be difficult (if in any condition the CMA varies between the preferred intervals, it cannot be considered a CMA) (44).…”
Section: Quality-by-design In the Development Of Analytical Methods And Pharmaceutical Manufacturingmentioning
confidence: 99%
“…In a recent study published by Saha et al (42) a simple, rapid and robust UPLC-MS method was developed for atazanavir sulphate using the AQbD approach. Implementing a combined technique of Ishikawa followed by FMEA risk analysis, factors (percent of organic modifier, flow rate and injection volume) that critically affect selected responses (analyte retention time, theoretical plate number, peak tailing and column) have been identified.…”
Section: Quality-by-design In the Development Of Analytical Methods And Pharmaceutical Manufacturingmentioning
confidence: 99%
See 2 more Smart Citations
“…Accordingly, this calls for development of a robust and sensitive LC-based analytical method for CHN [7]. The need for ultrafast separation, coupled with high efficiency and resolution, has leads to the emergence of an environment-friendly, cost-effective, and fast analytical technique of UHPLC [9][10][11]. Its distinct edge over traditional HPLC procedures is attributed to submicron sized particles of the stationary phase (i.e., <2 µm), leading eventually to the reduced sample run time, reduced consumption of solvents, lower back pressure, increased method efficiency, and reduction in the total expenditure involved during the analytical process [12][13][14][15].…”
Section: Introductionmentioning
confidence: 99%